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Objective. It has been suggested that atypical antipsychotics confer their effects via brain-derived neurotrophic factor (BDNF).
We investigated the effect of quetiapine on serum levels of BDNF and vascular endothelial growth factor (VEGF) in drug-naive
first-episode psychosis subjects. Methods. Fifteen patients drawn from a larger study received quetiapine treatment for twelve
weeks. Baseline levels of serum BDNF and VEGF were compared to age- and sex-matched healthy controls and to levels following
treatment. Linear regression analyses were performed to determine the relationship of BDNF and VEGF levels with outcome
measures at baseline and week 12. Results. The mean serum BDNF level was significantly higher at week 12 compared to baseline
and correlated with reductions in Brief Psychiatric Rating Scale (BPRS) and general psychopathology scores. Changes in serum
VEGF levels also correlated significantly with a reduction in BPRS scores, a significant improvement in PANNS positive symptoms
scores, and displayed a positive relationship with changes in BDNF levels. Conclusions. Our findings suggest that BDNF and VEGF
are potential biomarkers for gauging improvement of psychotic symptoms. This suggests a novel neurotrophic-based mechanism
of the drug effects of quetiapine on psychosis. This is the first report of VEGF perturbation in psychosis.
1. Introduction
The precise molecular mechanisms mediating the actions
of antipsychotic drugs remain poorly understood [1]. It has
been proposed that atypical antipsychotics confer some of
their benefits through neuroprotective effects [2]. Evidence
from rodent studies suggests that this protective effect is
mediated by an upregulation of brain-derived neurotrophic
factor (BDNF) in the brain [3–5]. A review of animal studies
concluded that, with the exception of risperidone, atypi-
cal antipsychotics might increase BDNF expression while
conventional antipsychotics might decrease expression [6].
Risperidone’s inability to alter expression of BDNF or to
even increase it at higher doses (Favelli) suggests differen-
tial effects of atypical antipsychotics on BDNF expression.
Olanzapine and risperidone significantly increaseD2 binding
in the medial prefrontal cortex and hippocampus, whilst
quetiapine does not. Similarly, olanzapine and risperidone
produce significant up-regulation of D4 receptors in the
hippocampus, caudate-putamen, and nucleus accumbens,
whilst quetiapine does not [7]. Quetiapine’s inability to
adjust dopamine receptors suggests that nondopaminergic
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mechanisms may contribute more to its efficacy than with
other atypical antipsychotics. Quetiapine has been shown to
attenuate stress-induced reductions in BDNF expression in
rats [5].
A previous study of drug-naive first-episode psychosis
patients reported that serum BDNF levels are lower in this
patient group and were increased toward healthy control
levels following olanzapine treatment, in association with a
reduction of positive symptoms [8].
Brain-Derived Neurotrophic Factor. BDNF is the most widely
distributed neurotrophin in the central nervous system
(CNS) [9] and is highly expressed in the prefrontal cortex
and hippocampus [10]. It serves a variety of essential func-
tions during development including neurogenesis, neuronal
differentiation and survival, and normal maturation of neu-
rodevelopmental pathways [11, 12]. In the adult, it continues to
play a crucial role in neuronal integrity, promoting synaptic
plasticity [13] as well as modulating synthesis, metabolism,
and release of dopamine, GABA, serotonin and glutamate
[14] and moderating use-dependent plasticity processes
including long-term potentiation, learning, and memory [15,
16]. Perturbations in BDNF are likely to have widespread
psychopathological consequences leading to altered brain
development and functioning [17], and there is accumulating
evidence that abnormal BDNF signalling may be involved
in the pathophysiology of a range of psychiatric disorders
including depression [18], bipolar affective disorder [19], and
schizophrenia [20].
There are several lines of evidence pointing to a pos-
sible role in schizophrenia. Firstly, BDNF is known to be
important both in the neurodevelopment of dopaminergic-
related systems and in ongoing dopaminergic function
[21], particularly exerting its effects through the mesolim-
bic pathway [22]. Secondly, as mentioned, BDNF regulates
other neurotransmitters putatively involved in the aetiology
of schizophrenia, including glutamate, GABA, and sero-
tonin [14]. Thirdly, BDNF principally exercises its influence
through neuroanatomical areas known to be associated with
symptom domains in schizophrenia, including the prefrontal
cortex and hippocampus [10].
Evidence for disturbed BDNF functioning in schizophre-
nia comes from several different sources. Several studies have
found alterations in postmortem levels of BDNF in the brains
of schizophrenic subjects: decreased levels in the prefrontal
cortex [23–25] and hippocampus [26] and increased levels
in the hippocampus [27, 28], anterior cingulate cortex [28],
and cerebral cortex [26]. Another study reported deceased
gene expression of BDNF and TrkB receptors in postmortem
schizophrenic brains [29]. BDNF is known to mediate its
effects through binding to TrkB receptors, which in turn
activate intracellular survival pathways [17].
BDNF crosses the blood-brain barrier [30] and serum
concentrations strongly correlate with brain levels [31].
Reports of BDNF levels in the serum of schizophrenic
patients have proven inconsistent. The majority demonstrate
a significant reduction in serum BDNF in chronic and medi-
cated schizophrenics compared to healthy controls [32–38],
though there have been reverse findings [39–41]. Similarly,
amongst first-episode and drug-naive cohorts, significant
reductions relative to healthy subjects have been reported
more often [42–49] than not [50–53]. Unlike postmortem
samples or chronic cohorts, FEP populations—especially
drug-na¨ıve ones—are beneficial to study as the effects of
chronicity, medication, and medical comorbidities are atten-
uated. A recent systematic review and meta-analysis con-
cluded that there was moderate evidence for reduced serum
BDNF levels in medicated and drug-naive schizophrenia,
with an association between reduced levels and increasing
age, but no effects of medication dosage [54]. However, the
reviewers were unable to account for the heterogeneity across
studies, though gender and body mass are known to affect
BDNF levels, as are stage of illness, subtype of schizophrenia
and medication [52], substance misuse [53] and diet [54].
Vascular Endothelial Growth Factor. The cytokine vascular
endothelial growth factor (VEGF) is critical for blood vessel
growth during embryonic development and in adults, pro-
moting vasculogenesis and playing a central role in wound
healing [55]. As well as indirectly promoting neurogenesis
by regulating brain angiogenesis, VEGF is also believed
to have direct trophic effects on neurons and glia in the
CNS, supporting neuronal migration in the developing CNS
and displaying essential neuroprotective properties in the
adult. While VEGF is believed to have significant effects
on hippocampal morphology [56] and its role in treating
depression has been explored [57], there has been little
research with respect to schizophrenia. There has been one
study that reported decreased VEGF mRNA levels in the
dorsolateral prefrontal cortex of schizophrenic subjects [58].
In rats, VEGF levels are increased in the hippocampus after
14 days of treatment with haloperidol and olanzapine. Upon
continuing with daily drug administration, it was found that
the effect of haloperidol was lost after 45 days of treatment
while VEGF levels continued to rise in the olanzapine-treated
rats. That difference was suggested to reflect the increased
efficacy in treating cognitive and negative symptoms that sec-
ond generation antipsychotics demonstrate [59]. In support
of this, chlorpromazine has been shown to reduce VEGF
secretion in vitro [60].
VEGF levels have not been measured in schizophrenic
subjects though there have been several studies in depression.
One study found raised plasma VEGF levels in 16 depressed
subjects [61] while another found raised levels in 35 depressed
subjects and 35 manic subjects compared to healthy controls.
The latter study also reported that there was no correlation of
VEGF levels to symptoms and the authors suggested that the
raised levels may be serving a neuroprotective function [62].
VEGF levels were not significantly altered by antidepressant
therapy in 25 depressed subjects [63], though one study
demonstrated significant increases in 19 depressed subjects
one month after ECT treatment that correlated with an
improvement in depression scores [64].
Aims. There have been no previous studies investigating
the effects of quetiapine on serum BDNF levels in FEP.
We therefore sought to compare baseline BDNF levels in
drug-naive FEP subjects with age- and sex-matched healthy
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controls and then to determine whether there was a change
in levels in FEP subjects following 12 weeks of treatment with
quetiapine. We hypothesised that baseline subjects would
have lower BDNF levels than healthy controls but that levels
would improve with treatment. We also hypothesised that
there would be a negative correlation between BDNF levels
and a number of outcome measures, including positive and
negative symptoms.
There has been no exploration of VEGF in schizophrenia
or other psychoses. We therefore sought to measure VEGF
levels in our sample. We hypothesised that baseline sub-
jects would have lower VEGF levels than healthy controls,
which would increase following quetiapine treatment. We
also hypothesized that changes to VEGF levels would be
negatively correlated to a number of outcome measures.
Finally, we proposed that therewould be a positive correlation
between BDNF and VEGF levels.
2. Materials and Methods
2.1. Subjects. 15 subjects (10 males/5 females; mean age =
18.6 ± 3.3 years) were drawn from a prospective, random-
ized, double-blind cohort study (Trial Registration: clin-
icaltrials.gov Identifier: NCT00449397) that compared 4-
weeks of 200mg/day versus 400mg/day of quetiapine for
efficacy, tolerability, and safety in 141 drug-naive first-episode
psychosis patients aged 15–25 [65]. All subjects who had
provided sufficient samples at baseline and week 12 had their
serum assayed. Eight subjects were completely drug-naive,
two subjects had received 3 days of quetiapine, four had
received 4 days of quetiapine, and one had received 7 days
of quetiapine prior to serum collection. Five subjects were
randomized to 200mg, ten to 400mg. The control group
consisted of a group of fifteen healthy volunteers with no
history of psychiatric disorder (18.5 ± 3.1 years). Subjects
were age- and sex-matched to controls because of the known
effects of age and gender [66]. The serum for all subjects was
separated in a centrifuge and stored at −80∘C until assayed.
A first episode of psychosis was defined as daily psychotic
symptoms for longer than a week that could not be explained
by other factors (e.g., organic in the context of temporal lobe
epilepsy or drug-induced psychotic episodes that remitted
within 7 days without antipsychotic medication. Subjects
were recruited from the Early Psychosis Prevention and
Intervention Centre (EPPIC), a subprogram of Orygen Youth
Health [67]. Exclusion criteria included having receivedmore
than one week of previous treatment with an antipsychotic,
a concurrent manic episode, and a history of neurological
disease. Subjects were randomly allocated to either 200mg or
400mg of quetiapine and treated for four weeks. Following
this, subjects remained on quetiapine for a further eight
weeks and had their doses adjusted according to clinical
need. No other antipsychotic was permitted during the twelve
week study. Subjects were assessed using SCID-IV, Research
Version, Patient Edition (2002), and symptomatology ratings
included the BPRS extended version 4, the Scale for the
Assessment of Negative Symptoms (SANS) and the Positive
and Negative Syndrome Scale (PANSS). Adverse events were
assessed using the Udvalg for Kliniske Undersogelser (UKU).
All raters undertook systematic psychopathology training
in the context of annual rater workshops at the Orygen
Research Centre; the ratings demonstrated good reliability,
with intraclass coefficients of agreement ≥0.8, and all were
within 20% of the standard scores. All raters were blind
to BDNF levels. The research was approved by the relevant
Research and Ethics Committees and both subjects and
controls provided written informed consent.
2.2. BDNF Measurement. BDNF concentrations of serum
samples were quantified using the BDNF Emax Immunoas-
say system (Promega, Madison, WI, USA) according to
manufacturer’s instructions. Briefly, each sample was diluted
with sample buffer to obtain two dilutions (1/10 and 1/50)
and each was assayed in triplicate. Technical replicates with
greater than 10% variance were repeated. After adjusting
for dilution factors, samples with greater than 25% variance
were repeated. The average serum concentration of BDNF of
both dilutions was determined and used for subsequent data
analysis.
2.3. VEGF Measurement. VEGF concentrations of serum
samples were quantified using MILLIPLEX MAP human
cytokine/chemokine panel (Cat. numberMPXHCYTO-60K,
Millipore, Billerica, MA, USA) in conjunction with a
Luminex 100 system (Austin, TX, USA). Undiluted samples
were assayed in duplicate and technical replicates with greater
than 10% variance were repeated. The serum concentration
of VEGF from both readouts was averaged and used for
subsequent data analysis.
2.4. Statistical Analyses. Data was analysed using GraphPad
Prism Version 6.1 (GraphPad Software, La Jolla, California,
USA). Data sets were separated according to sex and drug
dosage for analysis by one-way ANOVA using Bonferroni
adjusted 𝛼-values of 0.0167. 95% confidence intervals were
calculated and 𝑟2 values determined.
3. Results
3.1. BDNF. Serum BDNF levels of males and females in the
control group were similar, and this was also observed in
patient groups at week 0 and week 12 (data not shown).
Therefore, sexes were pooled for subsequent analyses. There
was no other significant effect of quetiapine dose on BDNF
levels in the patient group (data not shown) so both dosages
were pooled for subsequent analyses.
One-way ANOVA found a significant difference in the
mean serumBDNF levels between the groups (𝐹
(2,51)
= 7.797;
𝑃 = 0.0011; Figure 1(a)), and post hoc testing revealed that
this was significantly higher in the Week 12 patient group
compared to baseline (Wk12 versus Wk0: 𝑃 = 0.012) but not
compared to the control group (𝑃 = 0.0256).
Linear regression analysis found no significant relation-
ship between Week 0 serum BDNF levels and BPRS, UKU,
or SANS scores (see Supplementary Figures 1(a)–1(c) available
online at http://dx.doi.org/10.1155/2014/719395). There was
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Figure 1: Serum neurotrophin levels. Grouped analysis of serum BDNF levels (a) revealed a greater mean BDNF level of the FEP patient
group at week 12 compared to week 0. There was no overall difference in VEGF levels between the three subject groups (b). ∗One-way
ANOVA followed by post hoc t-test 𝑃 < 0.05.
also no relationship between serum BDNF levels and PANSS
negative, positive, or general psychopathology scores atWeek
0 (see Supplementary Figures 1(d)-1(e)). AtWeek 12, there was
no significant relationship between serum BDNF levels and
outcome scores (see Supplementary Figure 2).
The difference in serum BDNF levels at weeks 0 and 12
was determined and analysed against the change in evaluative
test scores. There was a significant positive relationship with
reduction in BPRS scores and change in BDNF levels (𝑟2 =
0.3656, 𝑃 = 0.0131) (Figure 2(a)), though there was no
significant relationship between the change in serum BDNF
levels and changes in UKU (𝑟2 = 0.08078, 𝑃 = 0.2861;
Figure 2(b)) or SANS scores (𝑟2 = 0.0569, 𝑃 = 0.3637;
Figure 2(c)).
The extent of the reduction in PANSS general psy-
chopathology scores displayed a positive relationshipwith the
change in BDNF levels (𝑟2 = 0.4176, 𝑃 = 0.0068; Figure 2(d))
but there was no significant relationship between the change
in BDNF levels and change in PANSS positive (𝑟2 = 0.1867,
𝑃 = 0.0946; Figure 2(e)) or negative scores (𝑟2 = 0.1037,
𝑃 = 0.2239; Figure 2(f)).
3.2. VEGF. Mean serum VEGF levels of males and females
in all three groups (control group, T0, and T12) did not differ
significantly (data not shown); therefore sexes were pooled
for subsequent analyses. There was no significant difference
in VEGF levels between patients allocated to dosage 1 and
dosage 2 at both week 0 and week 12 timepoints and patient
data for both dosages were pooled for subsequent analyses.
One-wayANOVA analysis of the pooled data revealed no sig-
nificant difference in the mean serum VEGF levels (𝐹
(2,45)
=
1.095, 𝑃 = 0.3437; Figure 1(b)).
Linear regression analysis found no significant relation-
ship between Week 0 serum VEGF levels and BPRS, UKU,
or SANS scores (Supplementry Figures 3(a)–3(c)). There was
also no relationship between serum BDNF levels and PANSS
negative, positive, or general psychopathology scores atWeek
0 (Supplementry Figures 3(d)–3(f)). Similarly, at Week 12,
there was no significant relationship between serum VEGF
levels and outcome scores (Supplementry Figure 4).
The difference in serum VEGF levels at weeks 0 and 12
was determined and analysed against the change in evaluative
test scores. There was a significant positive relationship with
reduction in BPRS scores and change in VEGF levels (𝑟2 =
0.3820, 𝑃 = 0.0244; Figure 3(a)), though there was no sig-
nificant relationship between change in UKU (𝑟2 = 0.03133,
𝑃 = 0.5629; Figure 3(b)) or SANS scores (𝑟2 = 0.0035, 𝑃 =
0.8473; Figure 3(c)) and the change in serum VEGF levels.
The change in VEGF levels displayed a significant positive
relationship with the reduction in PANSS positive symptom
scores (𝑟2 = 0.4847, 𝑃 = 0.0082; Figure 3(d)). However
there was no significant relationship between the change in
VEGF levels and change in PANSS negative (𝑟2 = 0.01708,
𝑃 = 0.6704; Figure 3(e)) or general scores (𝑟2 = 0.2457,
𝑃 = 0.0849; Figure 3(f)).
3.3. Relationship between BDNF and VEGF. We examined
the data set for a possible association between BDNF and
VEGF levels. Linear regression revealed that atWeek 0,VEGF
levels were significantly associated with BDNF levels (𝑟2 =
0.2833, 𝑃 = 0.0338; Figure 4(a)) but this relationship was
lost at the Week 12 timepoint (𝑟2 = 0.04886, 𝑃 = 0.4285;
Figure 4(b)). Furthermore, the change in BDNF levels from
Week 0 to Week 12 was significantly associated with changes
in VEGF levels (𝑟2 = 0.2758, 𝑃 = 0.0444; Figure 4(c)).
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Figure 2: Relationship between changes in serum BDNF concentrations with changes in outcome measures. There were significant positive
correlations between serum BDNF levels and improved scores on the BPRS (a) and PANNS general (f).There were no significant correlations
for changes in scores of UKU (b), SANS (c), PANSS negative (d), and PANSS positive (e) with the difference in BDNF levels across both time
points.
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Figure 3: Relationship between changes in serum VEGF concentrations with changes in outcome measures. There were significant positive
correlations between serumVEGF levels and improved scores on the BPRS (a) and PANNS positive (d).There were no significant correlations
for changes in scores of UKU (b), SANS (c), PANSS negative (d), and PANSS general (f) with the difference in VEGF levels across both time
points.
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Figure 4: Relationship between BDNF andVEGF levels. Correlation analysis of serumBDNF andVEGF levels at separate time points reveals
a significant relationship at week 0 (a) but not at week 12 (b). Further analysis found a significant correlation between the differences in BDNF
and VEGF levels (c).
4. Discussion
This study has uncovered a correlative relationship between
serum BDNF and VEGF levels in a drug-naive FEP sample.
Each was differentially altered by twelve weeks of quetiapine
treatment and was associated with specific measures of
psychopathology. We believe this is the first study reporting
on serum VEGF levels in first episode psychosis. The inverse
relationship of serum BDNF levels with BPRS and PANSS
general scores raises the possibility of its use in gauging
effective antipsychotic treatment for patients in the absence of
psychiatric evaluation.The study was limited by the relatively
small number of enrolled subjects who had provided both
baseline andWeek 12 blood samples; however, a high attrition
rate and loss to followup are widely acknowledged as two
significant challenges facing studies of this nature. Week 12
blood samples from the healthy control group were unavail-
able so we cannot definitively conclude that our observations
are solely attributable to quetiapine treatment. There was
also an imbalance in the male/female numbers so we were
unable to further examine the trend for males receiving the
higher dose of quetiapine to have higher BDNF levels. Finally,
full interpretation of our findings is hindered by the lack of
knowledge regarding the function of BDNF and VEGF in
peripheral circulation.
We found significantly raised BDNF levels following
three months of treatment with quetiapine. Furthermore, no
significant difference was found between Week 12 levels and
controls suggesting that BDNF levels normalise with treat-
ment. While there was no correlation between the absolute
serum concentration and outcome measures at baseline or
week 12, we found that the change in serum BDNF levels
was positively correlatedwith specific reductions inBPRS and
PANSS general psychopathology scores. No association was
found with PANNS positive, negative, SANS, or UKU scores.
It is known that negative symptoms take longer to respond
to treatment so it is possible that with extended treatment
beyond 12 weeks, changes in the other outcome measures
could display a relationship with BDNF levels. This could be
the focus of follow-up studies.
The few other studies that have attempted to corre-
late serum BDNF levels with outcome measures in FEP
have had mixed results. In a study of 15 FEP subjects,
a negative correlation between baseline BDNF levels and
positive symptom scores was found but not with negative
symptoms scores or any cognitive or motor function scores
[42]. In two separate studies, Rizos et al., found negative
correlations between baseline BDNF levels and both positive
and negative symptom scores in 14 FEP subjects [48] and
to the duration of untreated psychosis in 37 drug-naive
FEP subjects [47]. Only one other published FEP study has
correlated serum BDNF levels with outcome scores after
treatment with antipsychotics. Gonza´lez-Pinto et al. (2010)
found that serum BDNF levels were correlated to functional
outcome and improved positive symptoms, though not to
negative symptoms or general psychopathology in 11 olan-
zapine treated FEP subjects [44]. That study reported raised
serum BDNF levels following treatment with antipsychotics,
as have three other FEP studies (unspecified treatment [46];
aripiprazole [46]; risperidone, olanzapine, and aripiprazole
[53]) which are consistent with the findings of this study.
Amongst chronic cohorts, risperidone [47, 53], amisulpride
[47], and haloperidol [47] did not raise BDNF levels, whilst
clozapine [32, 68] and olanzapine [47] did. Collectively, there
is some evidence that outcome measures are associated with
serum BDNF levels, regardless of whether that relationship
is direct or indirect; however, further studies involving larger
cohorts of subjects and incorporating multiple antipsychotic
drugswill be required before amore definitive conclusion can
be reached.
Besides outcome measures, serum BDNF levels have
been positively correlated with right hippocampal volumes
in 20 drug-naive FEP subjects, with subjects having smaller
hippocampi than controls [69]. There has been extensive
research over the past decade examining the influence of
the val66met single nucleotide polymorphism (SNP) of
the BDNF gene [70] and its association with psychiatric
conditions including schizophrenia, anorexia nervosa [71],
and obsessive-compulsive disorder [72].While young healthy
carriers of the val66met polymorphism have smaller hip-
pocampi, older healthy carriers do not, although this dispar-
ity could be due to an age-by-allele interaction since both
BDNF expression and hippocampal volumes decrease with
age [73]. Studies in schizophrenic subjects have reported
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mixed findings, one study finding smaller volumes with the
met polymorphism [74], another smaller volumes with val
homozygotes [75], and three finding no association [76–78].
A recent study in first-episode psychosis (FEP) patients found
no difference in hippocampal volumes between healthy met
controls and FEP met carriers but reduced volumes for FEP
val homozygotes compared to healthy val controls. It would
be interesting to probe our dataset for associations between
BDNF, VEGF, and hippocampal volumes.
Beyond the hippocampus, others have found a relation-
ship between the met polymorphism, temporal, and occipital
lobe volume reductions and cognitive impairment [79], as
well as reduced frontal lobe volumes in FEP met carriers
compared to val homozygotes [80]. While the SNP has not
been shown to influence response to treatment [81], it has
been associated with an earlier age of onset of symptoms [82]
and the development of tardive dyskinesia [3, 83]; though
there have been negative findings [84, 85], the positive reports
complementing the findings of lower serum BDNF levels
amongst those with tardive dyskniesia [86, 87].
Though there was a trend for males on 400mg of
quetiapine to have higher BDNF levels at T12, no correlation
was found between dose of quetiapine and BDNF levels.
While this may have been due to low sample size or the fact
that the doses were too similar (and doses in both groups
were increased from week 4 to 12 according to clinical need),
the only other FEP study to correlate antipsychotic dose with
serum BDNF found no correlation with aripiprazole dose
[49]. This accords with the aforementioned meta-analysis
[54], though clozapine dose does correlate with serum BDNF
in chronic schizophrenia [32, 68].
To our knowledge this is the first report that serumBDNF
levels are increased by treatment with quetiapine in subjects
with psychosis and complements the other positive findings
of raised BDNF with atypical antipsychotic treatment and
improvement in outcome scores following treatment. It also
suggests a direct neurotrophic role for quetiapine via raising
BDNF. Quetiapine has been shown to decrease the stress-
induced reduction in BDNF expression in rat hippocampus
[5], increase BDNF mRNA expression in rat hippocam-
pus [88], and reverse the stress-induced suppression of rat
hippocampal neurogenesis [89]. Taken together with our
findings, these results suggest that quetiapine has a direct
neurotrophic effect in schizophrenia, promoting neuroplas-
ticity via the up-regulation of BDNF.
We also found that VEGF levels at baseline were signifi-
cantly associated with BDNF levels, though this relationship
was lost by Week 12. Nevertheless, the change in serum
BDNF levels from Week 0 to Week 12 was associated with a
change in serum VEGF levels. Furthermore, as with BDNF,
the increase in serum VEGF positively correlated with a
reduction in both BPRS and PANSS positive symptom scores.
This is the first study to measure serum VEGF levels in
psychosis and the findings are extremely novel. The cor-
relation between increases in VEGF and BDNF and their
similar impact on BPRS and general psychopathology scores
suggests a direct neurotrophic role for VEGF, independent of
secondary neurogenesis via brain angiogenesis. The findings
also suggest that any direct neurotrophic effect quetiapine
possesses maybe via several pathways including promoting
BDNF and VEGF expression. Finally, it raises the possibility
of gauging improvement of psychotic symptoms based by
measuring changes in serum levels of BDNF and VEGF.
5. Conclusion
Our study investigated the peripheral levels of two key neu-
rotrophic factors and report on their differential regulation
by quetiapine treatment. Our results revealed an intriguing
prospect that increases of serum BDNF levels might reflect
the positive behavioural effects of antipsychotic treatment.
Further research will be required to validate this as well as
to examine if other antipsychotic agents similarly moderate
VEGF levels.
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